

# Masakazu Toi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7893746/publications.pdf>

Version: 2024-02-01

165  
papers

8,842  
citations

126708

33  
h-index

48187

88  
g-index

172  
all docs

172  
docs citations

172  
times ranked

8135  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. <i>New England Journal of Medicine</i> , 2017, 376, 2147-2159.	13.9	1,228
2	MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2 <sup>-</sup> Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 2875-2884.	0.8	1,105
3	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3638-3646.	0.8	1,099
4	The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor <sup>+</sup> Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy <sup>+</sup> MONARCH 2. <i>JAMA Oncology</i> , 2020, 6, 116.	3.4	572
5	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2 <sup>-</sup> , Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020, 38, 3987-3998.	0.8	478
6	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235.	0.6	354
7	MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 5.	2.3	352
8	Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2 <sup>+</sup> Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 141-148.	0.8	327
9	Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. <i>Lancet Oncology</i> , The, 2015, 16, 816-829.	5.1	261
10	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. <i>Journal of Clinical Oncology</i> , 2021, 39, 1448-1457.	0.8	171
11	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer <sup>+</sup> The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1518-1530.	0.8	153
12	Clinical significance of the 21 <sup>+</sup> gene signature (Oncotype DX) in hormone receptor <sup>+</sup> positive early stage primary breast cancer in the Japanese population. <i>Cancer</i> , 2010, 116, 3112-3118.	2.0	104
13	Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 531-539.	1.1	97
14	Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2018, 110, 141-148.	3.0	97
15	Intravoxel Incoherent Motion and Quantitative Non-Gaussian Diffusion MR Imaging: Evaluation of the Diagnostic and Prognostic Value of Several Markers of Malignant and Benign Breast Lesions. <i>Radiology</i> , 2018, 287, 432-441.	3.6	93
16	Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 44-50.	0.7	90
17	Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis. <i>International Journal of Clinical Oncology</i> , 2017, 22, 11-17.	1.0	90
18	Insights Into Breast Cancer in the East vs the West. <i>JAMA Oncology</i> , 2019, 5, 1489.	3.4	90

#	ARTICLE	IF	CITATIONS
19	Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 129.	2.2	85
20	BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase IIâ€“DNA complexes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10642-E10651.	3.3	75
21	Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2â€“positive advanced breast cancer: Final results from MARIANNE. <i>Cancer</i> , 2019, 125, 3974-3984.	2.0	67
22	Visualising peripheral arterioles and venules through high-resolution and large-area photoacoustic imaging. <i>Scientific Reports</i> , 2018, 8, 14930.	1.6	62
23	Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 507-507.	0.8	55
24	Clinical Report on the First Prototype of a Photoacoustic Tomography System with Dual Illumination for Breast Cancer Imaging. <i>PLoS ONE</i> , 2015, 10, e0139113.	1.1	53
25	Real-time 3D Photoacoustic Visualization System with a Wide Field of View for Imaging Human Limbs. <i>F1000Research</i> , 2018, 7, 1813.	0.8	52
26	Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug. <i>Scientific Reports</i> , 2017, 7, 5987.	1.6	49
27	Photoacoustic mammography capable of simultaneously acquiring photoacoustic and ultrasound images. <i>Journal of Biomedical Optics</i> , 2016, 21, 116009.	1.4	48
28	Healthâ€“Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptorâ€“Positive, HER2â€“Negative Advanced Breast Cancer After Endocrine Therapy. <i>Oncologist</i> , 2020, 25, e243-e251.	1.9	45
29	Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24â€“weeks of aromatase inhibition. <i>Cancer Science</i> , 2011, 102, 858-865.	1.7	44
30	Neoadjuvant treatment for HER2-positive breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 32-32.	0.4	44
31	Palbociclib in combination with letrozole in patients with estrogen receptorâ€“positive, human epidermal growth factor receptor 2â€“negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. <i>International Journal of Clinical Oncology</i> , 2019, 24, 274-287.	1.0	43
32	Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. <i>BMC Cancer</i> , 2019, 19, 517.	1.1	42
33	Expansion of human Î³Î³ T cells for adoptive immunotherapy using a bisphosphonate prodrug. <i>Cancer Science</i> , 2018, 109, 587-599.	1.7	40
34	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2â€“Positive Early Breast Cancer: The Phase III KAITLIN Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 438-448.	0.8	35
35	Clinical Significance of <i>PIK3CA</i> and <i>ESR1</i> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant. <i>Clinical Cancer Research</i> , 2022, 28, 1500-1506.	3.2	35
36	SALL4 â€“KHDRBS3 network enhances stemness by modulating <i>CD44</i> splicing in basalâ€“like breast cancer. <i>Cancer Medicine</i> , 2018, 7, 454-462.	1.3	31

#	ARTICLE	IF	CITATIONS
37	Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. <i>Npj Breast Cancer</i> , 2021, 7, 80.	2.3	31
38	The Breast Cancer Working Group Presentation was Divided into Three Sections: The Epidemiology, Pathology and Treatment of Breast Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, i13-i18.	0.6	30
39	Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. <i>Cancer Science</i> , 2018, 109, 803-813.	1.7	29
40	Vascular branching point counts using photoacoustic imaging in the superficial layer of the breast: A potential biomarker for breast cancer. <i>Photoacoustics</i> , 2018, 11, 6-13.	4.4	28
41	Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. <i>International Journal of Cancer</i> , 2018, 143, 2905-2918.	2.3	28
42	Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR +, HER2 - Advanced Breast Cancer. <i>Oncologist</i> , 2020, 25, e1346-e1354.	1.9	28
43	Targeting Phosphorylation of Y-Box-Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 882-894.	1.9	27
44	High-resolution imaging mass spectrometry combined with transcriptomic analysis identified a link between fatty acid composition of phosphatidylinositols and the immune checkpoint pathway at the primary tumour site of breast cancer. <i>British Journal of Cancer</i> , 2020, 122, 245-257.	2.9	27
45	Genomic tumor evolution of breast cancer. <i>Breast Cancer</i> , 2016, 23, 4-11.	1.3	26
46	A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel+carboplatin+trastuzumab+pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 135-146.	1.1	26
47	Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma In Situ of Breast. <i>Frontiers in Oncology</i> , 2017, 7, 192.	1.3	25
48	Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer. <i>Oncotarget</i> , 2018, 9, 37216-37228.	0.8	24
49	Sal-like 4 protein levels in breast cancer cells are post-translationally down-regulated by tripartite motif-containing 21. <i>Journal of Biological Chemistry</i> , 2018, 293, 6556-6564.	1.6	23
50	Preoperative vascular mapping for anterolateral thigh flap surgeries: A clinical trial of photoacoustic tomography imaging. <i>Microsurgery</i> , 2020, 40, 324-330.	0.6	23
51	Efficacy of Scalp Cooling in Preventing and Recovering From Chemotherapy-Induced Alopecia in Breast Cancer Patients: The HOPE Study. <i>Frontiers in Oncology</i> , 2019, 9, 733.	1.3	22
52	Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. <i>Breast Cancer</i> , 2017, 24, 111-120.	1.3	21
53	Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. <i>Breast Cancer Research</i> , 2021, 23, 87.	2.2	21
54	Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants. <i>Communications Biology</i> , 2020, 3, 578.	2.0	20

#	ARTICLE	IF	CITATIONS
55	Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 417-428.	1.1	20
56	Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 500-500.	0.8	20
57	Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG. <i>Breast Cancer</i> , 2015, 22, 586-595.	1.3	19
58	The Sal-like 4 - integrin $\alpha 6 \beta 1$ network promotes cell migration for metastasis via activation of focal adhesion dynamics in basal-like breast cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2017, 1864, 76-88.	1.9	19
59	Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. <i>Breast Cancer Research</i> , 2017, 19, 47.	2.2	19
60	Development and clinical translation of photoacoustic mammography. <i>Biomedical Engineering Letters</i> , 2018, 8, 157-165.	2.1	18
61	Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer. <i>BMC Cancer</i> , 2010, 10, 56.	1.1	17
62	Abemaciclib for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 517-524.	0.9	17
63	Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. <i>ESMO Open</i> , 2019, 4, e000476.	2.0	17
64	Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients. <i>Breast Cancer</i> , 2019, 26, 282-289.	1.3	17
65	Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR. <i>International Journal of Molecular Sciences</i> , 2019, 20, 984.	1.8	16
66	Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. <i>ESMO Open</i> , 2018, 3, e000314.	2.0	15
67	Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. <i>Clinical Cancer Research</i> , 2018, 24, 3079-3086.	3.2	15
68	DNA damage repair functions and targeted treatment in breast cancer. <i>Breast Cancer</i> , 2020, 27, 355-362.	1.3	15
69	Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2 <sup>+</sup> advanced breast cancer: MONARCH 2 & 3 trials. <i>Cancer Science</i> , 2021, 112, 2381-2392.	1.7	15
70	A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance. <i>Breast Cancer</i> , 2014, 21, 20-27.	1.3	13
71	Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1002-1002.	0.8	13
72	Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. <i>European Journal of Cancer</i> , 2022, 166, 185-201.	1.3	13

#	ARTICLE	IF	CITATIONS
73	A snapshot of surgical resident training in Japan: results of a national-level needs assessment survey. <i>Surgery Today</i> , 2019, 49, 870-876.	0.7	11
74	Disruption of hypoxia-inducible fatty acid binding protein 7 induces beige fat-like differentiation and thermogenesis in breast cancer cells. <i>Cancer &amp; Metabolism</i> , 2020, 8, 13.	2.4	11
75	Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). <i>European Journal of Cancer</i> , 2021, 148, 287-296.	1.3	11
76	Oncobiology and treatment of breast cancer in young women. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 749-770.	2.7	11
77	Antitumor immunity and advances in cancer immunotherapy. <i>Breast Cancer</i> , 2017, 24, 1-2.	1.3	10
78	A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG07): therapeutic efficacy and clinical implications of circulating endothelial cells. <i>Cancer Medicine</i> , 2018, 7, 2442-2451.	1.3	10
79	Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. <i>Cancer Medicine</i> , 2018, 7, 3044-3056.	1.3	10
80	Downregulated ATP6V1B1 expression acidifies the intracellular environment of cancer cells leading to resistance to antibody-dependent cellular cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 817-830.	2.0	10
81	Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase III clinical trial. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 117-131.	1.1	10
82	Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. <i>Breast Cancer</i> , 2021, 28, 1038-1050.	1.3	10
83	MONARCH 3: A randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS624-TPS624.	0.8	10
84	MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1000-1000.	0.8	10
85	Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. <i>Breast Cancer</i> , 2022, 29, 174-184.	1.3	10
86	Estrogen Induces Mammary Ductal Dysplasia via the Upregulation of Myc Expression in a DNA-Repair-Deficient Condition. <i>IScience</i> , 2020, 23, 100821.	1.9	9
87	Identifying Gaps in the Locoregional Management of Early Breast Cancer: Highlights from the Kyoto Consensus Conference. <i>Annals of Surgical Oncology</i> , 2011, 18, 2885-2892.	0.7	8
88	An optical labeling-based proliferation assay system reveals the paracrine effect of interleukin-6 in breast cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 27-40.	1.9	8
89	A phase I pharmacokinetics/pharmacodynamics study of irinotecan combined with S <sup>1</sup> for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the Tj ETQq1130.784334 rgBT /O		
90	Factors associated with prolonged time to treatment failure with fulvestrant 500mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study. <i>Current Medical Research and Opinion</i> , 2018, 34, 49-54.	0.9	8

#	ARTICLE	IF	CITATIONS
91	Advances in EGFR/HER2-directed clinical research on breast cancer. <i>Advances in Cancer Research</i> , 2020, 147, 375-428.	1.9	8
92	BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS648-TPS648.	0.8	8
93	Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.. <i>Journal of Clinical Oncology</i> , 2015, 33, 512-512.	0.8	8
94	Phase III, randomized study of first-line trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs. trastuzumab + taxane (HT) treatment of HER2-positive MBC: Final overall survival (OS) and safety from MARIANNE.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1003-1003.	0.8	8
95	Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1049-1049.	0.8	8
96	Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels. <i>Cancer Management and Research</i> , 2022, Volume 14, 1179-1194.	0.9	8
97	Pertuzumab retreatment for HER2+ positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS). <i>Cancer Science</i> , 2022, 113, 3169-3179.	1.7	8
98	Analysis of the microvascular morphology and hemodynamics of breast cancer in mice using Spring-8 synchrotron radiation microangiography. <i>Journal of Synchrotron Radiation</i> , 2017, 24, 1039-1047.	1.0	7
99	The role of breast tomosynthesis in a predominantly dense breast population at a tertiary breast centre: breast density assessment and diagnostic performance in comparison with MRI. <i>European Radiology</i> , 2018, 28, 3194-3203.	2.3	7
100	Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 3-11.	0.6	7
101	Are graduating residents sufficiently competent? Results of a national gap analysis survey of program directors and graduating residents in Japan. <i>Surgery Today</i> , 2020, 50, 995-1001.	0.7	7
102	TDP2 suppresses genomic instability induced by androgens in the epithelial cells of prostate glands. <i>Genes To Cells</i> , 2020, 25, 450-465.	0.5	7
103	Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study. <i>Breast Cancer</i> , 2021, 28, 145-160.	1.3	7
104	The association of early toxicity and outcomes for patients treated with abemaciclib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1053-1053.	0.8	7
105	Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy. <i>International Journal of Oncology</i> , 2007, 31, 899-906.	1.4	7
106	Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer. <i>Breast Cancer</i> , 2009, 16, 207-218.	1.3	6
107	A homeobox protein, NKX6.1, up-regulates interleukin-6 expression for cell growth in basal-like breast cancer cells. <i>Experimental Cell Research</i> , 2016, 343, 177-189.	1.2	6
108	The impact of age on the risk of ipsilateral breast tumor recurrence after breast-conserving therapy in breast cancer patients with a 5mm margin treated without boost irradiation. <i>Radiation Oncology</i> , 2019, 14, 121.	1.2	6

#	ARTICLE	IF	CITATIONS
109	Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study. <i>Breast Cancer</i> , 2020, 27, 389-398.	1.3	6
110	Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines. <i>Biochemical and Biophysical Research Communications</i> , 2020, 526, 154-157.	1.0	6
111	Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan. <i>Breast Cancer</i> , 2022, 29, 1-8.	1.3	6
112	Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 919-926.	1.1	5
113	Downregulation of neuropilin-1 on macrophages modulates antibody-mediated tumoricidal activity. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1131-1142.	2.0	5
114	Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer. <i>Tumor Biology</i> , 2018, 40, 101042831881102.	0.8	5
115	Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. <i>Cancer Medicine</i> , 2019, 8, 5468-5481.	1.3	4
116	Digital artery deformation on movement of the proximal interphalangeal joint. <i>Journal of Hand Surgery: European Volume</i> , 2019, 44, 187-195.	0.5	4
117	Palbociclib as an early-line treatment for Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: a review of clinical trial and real-world data. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2179-2193.	1.0	4
118	Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an <i>ad hoc</i> analysis of the JBCRG-C06 Safari study. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 545-553.	0.6	4
119	Breast MR Image Fusion by Deformable Implicit Polynomial (DIP). <i>IPSJ Transactions on Computer Vision and Applications</i> , 2013, 5, 99-103.	4.4	3
120	Personalization of loco-regional care for primary breast cancer patients (part 2). <i>Future Oncology</i> , 2015, 11, 1301-1305.	1.1	3
121	5-Chloro-2,4-dihydropyridine, CDHP, prevents lung metastasis of basal-like breast cancer cells by reducing nascent adhesion formation. <i>Cancer Medicine</i> , 2018, 7, 463-470.	1.3	3
122	Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells. <i>Oncology Letters</i> , 2018, 17, 1153-1159.	0.8	3
123	In silico analysis-based identification of the target residue of integrin $\alpha 6$ for metastasis inhibition of basal-like breast cancer. <i>Genes To Cells</i> , 2019, 24, 596-607.	0.5	3
124	Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19). <i>International Journal of Clinical Oncology</i> , 2021, 26, 1229-1236.	1.0	3
125	Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population. <i>Cancer Science</i> , 2021, 112, 3338-3348.	1.7	3
126	MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2 <sup>-</sup> Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5801-5809.	3.2	3



#	ARTICLE	IF	CITATIONS
127	Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study). <i>Cancers</i> , 2021, 13, 4008.	1.7	3
128	The effects of frozen gloves and socks on paclitaxel-induced peripheral neuropathy among patients with breast cancer: A self-controlled clinical trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10022-10022.	0.8	3
129	Three-dimensional visualization of thoracodorsal artery perforators using photoacoustic imaging. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2022, 75, 3166-3173.	0.5	3
130	Is there disparity between regions and facilities in surgical resident training in Japan? Insights from a national survey. <i>Surgery Today</i> , 2020, 50, 1585-1593.	0.7	2
131	Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial. <i>Cancer Medicine</i> , 2020, 9, 9246-9255.	1.3	2
132	Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.. <i>Journal of Clinical Oncology</i> , 2021, 39, 518-518.	0.8	2
133	Analysis of tumor infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16).. <i>Journal of Clinical Oncology</i> , 2016, 34, 599-599.	0.8	2
134	Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1048-1048.	0.8	2
135	MONARCH 2: Subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1061-1061.	0.8	2
136	Comment and reply on: Vasohibin-1 and its emerging role in the evolution and progression of systemic tumors besides renal cell carcinomas. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 105-106.	1.5	1
137	Development of Photoacoustic Mammography for Detection of Breast Cancer. <i>Nippon Laser Igakkaishi</i> , 2013, 34, 24-29.	0.0	1
138	RE: Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	1
139	Data of a fluorescent imaging-based analysis of anti-cancer drug effects on three-dimensional cultures of breast cancer cells. <i>Data in Brief</i> , 2015, 5, 429-433.	0.5	1
140	Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan. <i>Breast Cancer: Basic and Clinical Research</i> , 2019, 13, 117822341882513.	0.6	1
141	Favorable prognostic factors of oligometastatic breast cancer: A subset analysis of OLIGO-BC1.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1026-1026.	0.8	1
142	A Novel Real-time Navigation System for Lymphaticovenular Anastomosis Using Projection Mapping with Indocyanine Green Fluorescence. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2021, 9, e3758.	0.3	1
143	Bevacizumab plus paclitaxel optimization study with interventional maintenance endocrine therapy in advanced or metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 (BOOSTER) trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS657-TPS657.	0.8	1
144	Near infrared imaging using indocyanine green for sentinel lymph node biopsy in women with early breast cancer: Results of a meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e12044-e12044.	0.8	1

#	ARTICLE	IF	CITATIONS
145	Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03).. Journal of Clinical Oncology, 2017, 35, 1025-1025.	0.8	1
146	International retrospective cohort study of locoregional and systemic therapy in oligometastatic breast cancer (OLIGO-BC1).. Journal of Clinical Oncology, 2020, 38, 1025-1025.	0.8	1
147	Lapatinib. Drugs, 2007, 67, 2109-2110.	4.9	0
148	Supplementation with Fermented Barley Extract Prevents Mammary Epithelial Cell Invasion in an Early Breast Cancer Model. Acta Histochemica Et Cytochemica, 2021, 54, 73-78.	0.8	0
149	Reply to K. Hashimoto and A. Shimomura. Journal of Clinical Oncology, 2021, 39, 1507-1508.	0.8	0
150	Next-Generation Clinical Trials and Research with Successful Collaborations. Advances in Experimental Medicine and Biology, 2021, 1187, 613-622.	0.8	0
151	Comprehensive analysis of serum N-glycans as a biomarker for breast cancer.. Journal of Clinical Oncology, 2012, 30, e21031-e21031.	0.8	0
152	Activation by zoledronic acid and IL-18 of $\gamma\delta$ T cells from early-stage breast cancer patients in the context of helper NK cells.. Journal of Clinical Oncology, 2012, 30, e21004-e21004.	0.8	0
153	Effect of orally administered S-1 on circulating endothelial cells in patients with metastatic breast cancer.. Journal of Clinical Oncology, 2012, 30, e21052-e21052.	0.8	0
154	PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.. Journal of Clinical Oncology, 2016, 34, TPS636-TPS636.	0.8	0
155	Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17).. Journal of Clinical Oncology, 2016, 34, 1027-1027.	0.8	0
156	Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for HER2-positive advanced breast cancer.. Journal of Clinical Oncology, 2016, 34, 593-593.	0.8	0
157	Sentinel lymph node biopsy using indocyanine green fluorescence navigation method after neoadjuvant chemotherapy for patients with clinically node-positive breast cancer.. Journal of Clinical Oncology, 2017, 35, e12108-e12108.	0.8	0
158	The long-lasting anti-tumor activity of cisplatin affecting the sustainable systemic immune alteration may improve distant-disease free survival of triple-negative breast cancer in patients with a substantial residual tumor following preoperative chemotherapy: A retrospective analysis with translational research.. Journal of Clinical Oncology, 2020, 38, e12631-e12631.	0.8	0
159	Predicting the efficacy of nivolumab combined with radiation therapy by longitudinal liquid biopsy with artificial intelligence for patients with metastatic breast cancer (translational research of the Tj ETQq1 1 0.78031 4 rgBT0/Overlo	0.8	0
160	Estimation of absolute benefit of S-1 postoperative therapy for ER-positive, HER2-negative breast cancer: Exploratory analysis of the phase III potent trial.. Journal of Clinical Oncology, 2020, 38, 532-532.	0.8	0
161	SL-2 Breast cancer treatment system. Neuro-Oncology Advances, 2020, 2, ii1-ii1.	0.4	0
162	Abstract P5-13-36: Germline $\langle i \rangle$ BRCA $\langle /i \rangle$ 1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study. Cancer Research, 2022, 82, P5-13-36-P5-13-36.	0.4	0

#	ARTICLE	IF	CITATIONS
163	Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib. Cancer Research, 2022, 82, PD2-04-PD2-04.	0.4	0
164	Trends in breast cancer treatment: Focusing on tumor subtype-specific treatment. Tenri Medical Bulletin, 2011, 14, 1-25.	0.1	0
165	Abstract 6085: Clonal evolution of mammary epithelial cells into breast cancers. Cancer Research, 2022, 82, 6085-6085.	0.4	0